Even if the PD1/PDL1 axis seems to be an interesting target because most multiple myeloma cells express PDL1, the use of immune checkpoint inhibitors (ICIs) in monotherapy did not provide any clinical benefit in these patients in previous reports [18]. This evidence concerns the gene CD274 and AL amyloidosis.